VTRS

Viatris
D

VTRS

10.645
USD
-0.06
(-0.51%)
مغلق
حجم التداول
171,374
الربح لكل سهم
2
العائد الربحي
4.51
P/E
-4
حجم السوق
12,410,708,792
أصول ذات صلة
ABBV
ABBV
1.105
(0.53%)
210.630 USD
AZN
AZN
0.510
(0.63%)
80.970 USD
BMY
BMY
-0.520
(-1.07%)
47.890 USD
GSK
GSK
0.100
(0.25%)
40.190 USD
JNJ
JNJ
0.230
(0.13%)
179.250 USD
MRK
MRK
1.235
(1.43%)
87.370 USD
PFE
PFE
0.155
(0.60%)
25.870 USD
P
PRGO
1.050
(4.48%)
24.490 USD
REGN
REGN
-8.70
(-1.45%)
589.55 USD
المزيد
الأخبار المقالات

العنوان: Viatris

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.